One-Time gene infusion aims to fix inherited heart disease

NCT ID NCT05885412

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a single intravenous dose of a gene therapy called RP-A601 in 9 adults with a genetic heart condition (PKP2-ACM) that causes dangerous heart rhythms and heart failure. The therapy delivers a working copy of the PKP2 gene to heart cells to restore protein function. The main goal is to check safety, but researchers will also measure changes in heart rhythm and protein levels.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PKP2 ARRHYTHMOGENIC CARDIOMYOPATHY (PKP2-ACM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

arrhythmogenic right ventricular cardiomyopathy arrhythmogenic right ventricular dysplasia 9 cardiac arrest Death, Sudden, Cardiac

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Children's Hospital of Philadelphia

    WITHDRAWN

    Philadelphia, Pennsylvania, 19104, United States

  • Duke University

    RECRUITING

    Durham, North Carolina, 27710, United States

    Contact

    Contact Email: •••••@•••••

  • University of California, San Diego

    RECRUITING

    La Jolla, California, 92037, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••